Document and Entity Information [Abstract] Document Type Document Annual Report Document Period End Date Document Transition Report Securities Act File Number Entity Registrant Name Entity Incorporation, State or Country Code Entity Tax Identification Number Entity Address, Address Line One Entity Address, City or Town Entity Address, State or Province Entity Address, Postal Zip Code City Area Code Local Phone Number Title of 12(b) Security Trading Symbol Security Exchange Name Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Entity Ex Transition Period ICFR Auditor Attestation Flag Document Financial Statement Error Correction [Flag] Document Financial Statement Error Correction Entity Shell Company Entity Public Float Entity Common Stock, Shares Outstanding Auditor Name Auditor Location Auditor Firm ID Entity Central Index Key Current Fiscal Year End Date Document Fiscal Year Focus Document Fiscal Period Focus Amendment Flag BALANCE SHEETS Statement [Table] Class of Stock [Axis] Class of Stock [Domain] Represents information relating to Series A convertible preferred stock. Series A Convertible Preferred Stock [Member] Series A convertible preferred stock Represents information relating to Series B convertible preferred stock. Series B Convertible Preferred Stock [Member] Series B convertible preferred stock Statement [Line Items] Statement Assets [Abstract] Assets Assets, Current [Abstract] Current assets: Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents Short-Term Investments Short-term investments Prepaid Expense and Other Assets, Current Prepaid expenses and other current assets Total Assets, Current Total current assets Long-Term Investments Long-term investments Operating Lease, Right-of-Use Asset Right of use assets - operating leases Deferred Costs, Noncurrent Deferred offering costs Other Assets, Noncurrent Other assets Assets Total assets Liabilities and Equity [Abstract] Liabilities, Convertible Preferred Stock and Stockholders' Equity (Deficit) Liabilities [Abstract] Liabilities Liabilities, Current [Abstract] Current liabilities: Accounts Payable, Current Accounts payable Accrued Liabilities, Current Accrued expenses Total Operating Lease, Liability, Current Operating lease liabilities Liabilities, Current Total current liabilities Operating Lease, Liability, Noncurrent Operating lease liabilities, net of current amount Liabilities Total liabilities Commitments and Contingencies. Commitments and contingencies (Note 7) Temporary Equity, Carrying Amount, Attributable to Parent Ending balance Beginning balance Convertible preferred stock Equity, Attributable to Parent [Abstract] Stockholders' equity (deficit): Preferred Stock, Value, Issued Preferred stock $0.0001 par value, 10,000,000 shares authorized; no shares issued and outstanding Common Stock, Value, Issued Common stock $0.0001 par value, 200,000,000 shares authorized; 33,706,765 and 2,745,480 shares issued and outstanding at December 31, 2024 and 2023, respectively Additional Paid in Capital Additional paid-in capital Retained Earnings (Accumulated Deficit) Accumulated deficit Accumulated deficit Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated other comprehensive (loss) Equity, Attributable to Parent Ending balance Beginning balance Total stockholders' equity (deficit) Liabilities and Equity Total liabilities, convertible preferred stock and stockholders' equity (deficit) Temporary Equity, Par or Stated Value Per Share Convertible preferred stock, par value (in dollars per share) Temporary Equity, Shares Authorized Convertible preferred stock, shares authorized (in shares) Temporary Equity, Shares Issued Ending balance (in shares) Beginning balance (in shares) Convertible preferred stock, shares issued (in shares) Temporary Equity, Shares Outstanding Convertible preferred stock, shares outstanding (in shares) Preferred Stock, Par or Stated Value Per Share Preferred stock, par value (in dollars per share) Preferred Stock, Shares Authorized Preferred stock, shares authorized (in shares) Preferred Stock, Shares Issued Preferred stock, shares issued (in shares) Preferred Stock, Shares Outstanding Preferred stock, shares outstanding (in shares) Common Stock, Par or Stated Value Per Share Common stock, par value (in dollars per share) Common Stock, Shares Authorized Common stock, shares authorized (in shares) Common Stock, Shares, Issued Common stock, shares issued (in shares) Common Stock, Shares, Outstanding Common stock, shares outstanding (in shares) STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS Operating Expenses [Abstract] Operating expenses: Research and Development Expense Research and development Total Firmonertinib General and Administrative Expense General and administrative Operating Expenses Total operating expenses Operating Income (Loss) Operating loss Investment Income, Net Interest and investment income Net loss OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax Unrealized (loss) on marketable securities, net of tax Unrealized (loss) on marketable securities Other Comprehensive Income (Loss), Net of Tax Total other comprehensive (loss) Comprehensive Income (Loss), Net of Tax, Attributable to Parent Total comprehensive loss Earnings Per Share [Abstract] Share information: Earnings Per Share, Basic Net loss per share attributable to common stockholders, basic (in dollars per share) Earnings Per Share, Diluted Net loss per share attributable to common stockholders, diluted (in dollars per share) Weighted Average Number of Shares Outstanding, Basic Weighted-average shares of common stock outstanding, basic (in shares) Weighted Average Number of Shares Outstanding, Diluted Weighted-average shares of common stock outstanding, diluted (in shares) STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) Equity Components [Axis] Equity Component [Domain] Common Stock [Member] Common stock Additional Paid-in Capital [Member] Additional paid-in capital AOCI Attributable to Parent [Member] Accumulated Other Comprehensive (Loss) Retained Earnings [Member] Accumulated deficit Increase (Decrease) in Temporary Equity [Roll Forward] Change in convertible preferred stock Shares, Outstanding Ending balance (in shares) Beginning balance (in shares) Temporary Equity, Stock Issued During Period, Value, New Issues Issuance of Convertible preferred stock at $1.05 per share, net of issuance costs Number of new stock classified as temporary equity issued during the period. Temporary Equity, Stock Issued During Period, Shares, New Issues Issuance of convertible preferred stock (in shares) Issuance of Convertible preferred stock at $1.05 per share, net of issuance costs (in shares) Stock Issued During Period, Value, New Issues Issuance of common stock in initial public offering, net of issuance costs of $18,032 Stock Issued During Period, Shares, New Issues Issuance of common stock in initial public offering, net of issuance costs of $18,032 (in shares) Issuance of common stock in initial public offering (in shares) Stock Repurchased During Period, Shares Repurchase of common stock (in shares) The gross value of conversion of temporary equity to common stock during the period. Temporary Equity, Value, Conversion to Common Stock Conversion of convertible preferred stock into common stock Number of shares converted from temporary equity to common stock during the period. Temporary Equity, Shares, Conversion to Common Stock Conversion of convertible preferred stock into common stock (in shares) Stock Issued During Period, Value, Conversion of Convertible Securities Conversion of convertible preferred stock into common stock Stock Issued During Period, Shares, Conversion of Convertible Securities Conversion of convertible preferred stock into common stock (in shares) Conversion of convertible preferred stock into common stock (in shares) Stock Issued During Period, Value, Stock Options Exercised Exercise of stock options Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Exercised (in shares) Exercise of stock options (in shares) APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Stock-based compensation expense Per share or per unit amount of temporary equity issued. Temporary Equity, Share Issued, Price Per Share Convertible preferred stock, issued price per share The cost incurred in connection with issuance of temporary equity. Temporary Equity, Issuance Costs Issuance costs Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs Issuance costs STATEMENTS OF CASH FLOWS Net Cash Provided by (Used in) Operating Activities [Abstract] Cash flows from operating activities: Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net loss Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustment to reconcile net loss to net cash used in operating activities: Share-Based Payment Arrangement, Noncash Expense Stock-based compensation expense Increase (Decrease) in Operating Capital [Abstract] Changes in operating assets and liabilities: Increase (Decrease) in Prepaid Expense and Other Assets Prepaid expenses and other current assets Increase (Decrease) in Other Operating Assets Other assets Increase (Decrease) in Accounts Payable, Trade Accounts payable Increase (Decrease) in Accrued Liabilities Accrued expenses Increase (Decrease) in Operating Lease Liability Operating lease liabilities Net Cash Provided by (Used in) Operating Activities Net cash used in operating activities Net Cash Provided by (Used in) Investing Activities [Abstract] Cash flows from investing activities: Payments to Acquire Short-Term Investments Purchase of short-term investments Proceeds from Maturities, Prepayments and Calls of Short-Term Investments Maturity of short-term investments Net Cash Provided by (Used in) Investing Activities Net cash used in investing activities Net Cash Provided by (Used in) Financing Activities [Abstract] Cash flows from financing activities: Proceeds from Issuance Initial Public Offering Proceeds from issuance of common stock in an initial public offering, net of issuance costs Proceeds from Stock Options Exercised Proceeds from the exercise of stock options Proceeds from Issuance of Convertible Preferred Stock Proceeds from the sale of Series B convertible preferred stock, net of issuance costs Payments of Stock Issuance Costs Payment of deferred offering costs Net Cash Provided by (Used in) Financing Activities Net cash provided by financing activities Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Net (decrease) in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Cash and cash equivalents at end of the year Cash and cash equivalents at beginning of the year Noncash Investing and Financing Items [Abstract] Supplemental disclosures of non-cash financing and investing activities Specific incremental costs directly attributable to a proposed or actual offering of securities transferred to additional paid in capital during the period. Deferred Offering Costs Transferred to Additional Paid in Capital Deferred offering costs transferred to additional paid in capital Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period. Deferred Offering Costs Included in Accounts Payable Deferred offering costs in accounts payable Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Right-of-use assets obtained in exchange for new operating lease liabilities No definition available. Background Nature of Operations [Text Block] Background No definition available. Development-Stage Risks and Liquidity The entire disclosure for development stage risks and liquidity. Development Stage Risks and Liquidity [Text Block] Development-Stage Risks and Liquidity Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Summary of Significant Accounting Policies Fair Value Measurements Fair Value Disclosures [Text Block] Fair Value Measurements Prepaid Expenses and Other Current Assets The entire disclosure for prepaid expenses and other current assets. Prepaid Expenses and Other Current Assets [Text block] Prepaid Expenses and Other Current Assets Accrued Expenses Accounts Payable and Accrued Liabilities Disclosure [Text Block] Accrued Expenses Commitments and contingencies Commitments and Contingencies Disclosure [Text Block] Commitments and contingencies No definition available. Convertible Preferred Stock and Common Stock The entire disclosure for temporary equity and equity. Temporary Equity and Equity Disclosure [Text Block] Convertible Preferred Stock and Common Stock Stock-based Compensation Share-Based Payment Arrangement [Text Block] Stock-based Compensation Income Taxes Income Tax Disclosure [Text Block] Income Taxes No definition available. License and Collaboration Agreements The entire disclosure for licenses and arrangements other than collaborative applicable to revenue-generating activity or operations. License and Arrangements [Text Block] License and Collaborative Agreements Segment Information Segment Reporting Disclosure [Text Block] Segment Information Subsequent Event Subsequent Events [Text Block] Subsequent Event Basis of Accounting, Policy [Policy Text Block] Basis of Presentation Use of Estimates, Policy [Policy Text Block] Use of Estimates Fair Value Measurement, Policy [Policy Text Block] Fair Value Measurements Cash and Cash Equivalents, Policy [Policy Text Block] Cash equivalents Investment, Policy [Policy Text Block] Investments Concentration Risk, Credit Risk, Policy [Policy Text Block] Concentration of credit risk Lessee, Leases [Policy Text Block] Leases Research and Development Expense, Policy [Policy Text Block] Research and Development Costs Share-Based Payment Arrangement [Policy Text Block] Stock-Based Compensation Expense Earnings Per Share, Policy [Policy Text Block] Net Loss per Share Income Tax, Policy [Policy Text Block] Income Taxes New Accounting Pronouncements, Policy [Policy Text Block] Accounting Pronouncements Recently Adopted and Accounting Pronouncements Not Yet Adopted Stockholders' Equity, Policy [Policy Text Block] Reverse Stock Split Disclosure of accounting policy for license and collaboration agreements. License and Collaboration Agreements, Policy [Policy Text Block] License and Collaboration Agreements Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Schedule of computation of net loss, basic and diluted Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Schedule of potentially dilutive securities have been excluded from the computation of diluted weighted-average shares Fair Value, Assets Measured on Recurring Basis [Table Text Block] Schedule of company's financial assets measured at fair value on a recurring basis Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block] Schedule of prepaid expenses and other current assets Schedule of Accrued Liabilities [Table Text Block] Schedule of Accrued expenses, current Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Schedule of future maturities of operating lease payments Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Schedule of stock-based compensation expense Share-Based Payment Arrangement, Option, Activity [Table Text Block] Schedule of of stock options activity under the Plan Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Schedule of assumptions used in estimating the fair value of options Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Schedule of reconciliation of income tax benefit at the statutory federal income tax rate and income taxes Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Schedule of deferred tax assets and liabilities for federal income taxes Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block] Schedule of significant expense categories Stock, Class of Stock [Table] Sale of Stock [Axis] Sale of Stock [Domain] IPO [Member] IPO Over-Allotment Option [Member] Underwriters allotment Class of Stock [Line Items] Background Shares Issued, Price Per Share Share price (in dollars per share) The cash inflow associated with the amount received from entity's first offering of stock to the public, net of underwriting discounts and commissions and other offering expenses. Proceeds from Issuance Initial Public Offering, Net Proceeds from issuance of common stock in an initial public offering, net of underwriting discounts and commissions and other offering expenses Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year or longer ( the normal operating cycle if longer or (longer than one operating cycle) and may include trading securities, available-for-sale securities, or held-to-maturity securities, as applicable. Cash Cash Equivalents, Short Term Investments And Long Term Investments Cash and cash equivalents, and short and long-term investments Substantial Doubt about Going Concern, within One Year [true false] Substantial doubt about ability to continue as going concern within one year Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers Into Level 3 Fair value, measurement with unobservable inputs reconciliation, liability, transfers into level 3 Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers out of Level 3 Fair value, measurement with unobservable inputs reconciliation, liability, transfers out of level 3 Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Transfers Into Level 3 Fair value, measurement with unobservable inputs reconciliation, recurring basis, asset transfers into level 3 Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3 Fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, transfers out of level 3 Amount of transfers of liabilities measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2. Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Level 1 to Level 2 Transfers Fair value, measurement with unobservable inputs reconciliation, liability, level 1 to level 2 transfers Amount of transfers of liabilities measured on a recurring basis out of Level 2 of the fair value hierarchy into Level 1. Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Level 2 to Level 1 Transfers Fair value, measurement with unobservable inputs reconciliation, liability, level 2 to level 1 transfers Amount of transfers of assets measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Level 1 to Level 2 Transfers Fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, level 1 to level 2 transfers Amount of transfers of assets measured on a recurring basis out of Level 2 of the fair value hierarchy into Level 1. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Level 2 to Level 1 Transfers Fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, level 2 to level 1 transfers Cash Equivalents, at Carrying Value Cash equivalents Net Income (Loss) Available to Common Stockholders, Basic [Abstract] Numerator: Net Income (Loss) Available to Common Stockholders, Basic Net loss (basic) Net Income (Loss) Available to Common Stockholders, Diluted Net loss (diluted) Weighted Average Number of Shares Outstanding, Diluted [Abstract] Denominator: Weighted Average Number of Shares Issued, Basic Weighted-average shares of common stock outstanding Weighted Average Number of Shares, Common Stock Subject to Repurchase or Cancellation Less: Weighted-average shares of common stock subject to repurchase Antidilutive Security, Excluded EPS Calculation [Table] Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Convertible Preferred Stock [Member] Convertible preferred stock Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive securities Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Potentially dilutive securities have been excluded from the computation of diluted weighted-average shares Stockholders' Equity Note, Stock Split, Conversion Ratio Stock split conversion ratio Fair Value, Recurring and Nonrecurring [Table] Measurement Basis [Axis] Portion at Fair Value Measurement [Member] Reported Value Measurement [Member] Amortized Cost Estimate of Fair Value Measurement [Member] Fair Value Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Domain] Fair Value, Inputs, Level 1 [Member] Level 1 Fair Value, Inputs, Level 2 [Member] Level 2 Asset Class [Axis] Asset Class [Domain] Corporate Debt Securities [Member] Corporate securities US Government Agencies Debt Securities [Member] Government securities Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value Measurements Cash and Cash Equivalents, Fair Value Disclosure Money market funds Debt Securities, Available-for-Sale Securities, Fair Value Debt Securities, Available-for-Sale, Amortized Cost Securities, Carrying Value Assets, Fair Value Disclosure Total assets measured at fair value Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Gross Unrealized Gains Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Gross Unrealized Losses Cash Cash balance Amount of asset related to consideration paid in advance for research and development that provides economic benefits within a future period of one year or the normal operating cycle, if longer. Prepaid Research and Development Research and development Amount of asset related to consideration paid in advance for professional fees that provides economic benefits within a future period of one year or the normal operating cycle, if longer. Prepaid Professional Fees Professional fees Prepaid Insurance Insurance Carrying amount as of the balance sheet date of income taxes previously overpaid to tax authorities (such as U.S. Federal, state and local tax authorities) representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes. Also called income tax refund receivable. Tax Credit Receivable, Current Tax credit receivable Carrying value as of the balance sheet date of the obligations incurred through that date and payable for research and development expense. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Accrued Research And Development, Current Research and development Accrued Professional Fees, Current Professional fees Employee-related Liabilities, Current Compensation and related expenses Other Accrued Liabilities, Current Other accrued expenses Lessee, Lease, Description [Table] Lessee, Lease, Description [Line Items] Leases Number of operating leases that are subleases for office space. Number of Operating Leases, Subleases Number of operating leases that are subleases for office space Number of operating leases with subleases commencing for office space during the period. Number of Operating Leases, Sublease Commencing Number of subleases commencing during the period Operating Lease, Expense Operating lease expense Operating Lease, Weighted Average Remaining Lease Term Remaining lease term Operating Lease, Weighted Average Discount Rate, Percent Discount rate (as a percent) Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract] Future maturities of operating lease liabilities Lessee, Operating Lease, Liability, to be Paid, Year One 2025 Lessee, Operating Lease, Liability, to be Paid, Year Two 2026 Lessee, Operating Lease, Liability, to be Paid Total future minimum payments Lessee, Operating Lease, Liability, Undiscounted Excess Amount Less imputed interest Operating Lease, Liability Present value of lease liabilities Payments for Rent Cash paid for rent expense Defined Contribution Plan, Employer Matching Contribution, Percent of Match Percentage employer matches of the employee's percentage contribution Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay Percentage of employee's gross pay for which the employer contributes a matching contribution Defined Contribution Plan, Cost Company contributions (in dollars) Temporary Equity, by Class of Stock [Table] Temporary Equity [Line Items] Convertible Preferred Stock and Common Stock Per share or per unit amount of temporary equity issued. Temporary Equity, Shares Issued, Price Per Share Issue price (in dollars per share) Represents number of voting rights of common stock per share. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights. Common Stock, Voting Rights, Per Share Common stock voting right per share Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Plan Name [Axis] Plan Name [Domain] 2021 Employee, Director and Consultant Equity Incentive Plan (the "Plan"). Employee, Director and Consultant Equity Incentive Plan, 2021 [Member] 2021 Plan 2024 Employee, Director and Consultant Equity Incentive Plan (the "Plan"). Employee, Director and Consultant Equity Incentive Plan, 2024 [Member] 2024 Plan Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Stock-based Compensation Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized Shares authorized Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized Additional shares authorized Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Shares available for grant Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Vesting Period Statement of Income Location, Balance [Axis] Statement of Income Location, Balance [Domain] Research and Development Expense [Member] Research and development General and Administrative Expense [Member] General and administrative Share-Based Payment Arrangement, Expense Stock-based compensation expense Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Options Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Outstanding as of end of period (in shares) Outstanding as of beginning of period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period Forfeited/Expired (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Exercisable (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Vested and expected to vest (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Weighted average exercise price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Outstanding as of end of period (in dollars per shares) Outstanding as of beginning of period (in dollars per shares) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Granted (in dollars per shares) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Exercised (in dollars per shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price Forfeited/expired (in dollars per shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Exercisable (in dollars per shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Vested and expected to vest (in dollars per shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract] Weighted average remaining contractual term (years) and Aggregate Intrinsic Value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Weighted average remaining contractual term - Outstanding (years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Weighted average remaining contractual term - Exercisable (years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term Weighted average remaining contractual term - Vested and expected to vest (years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Aggregate Intrinsic Value - Outstanding (in dollars) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Aggregate Intrinsic Value - Exercisable (in dollars) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Aggregate Intrinsic Value - Vested and expected to vest (in dollars) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Weighted-average grant-date fair value of options Statistical Measurement [Axis] Statistical Measurement [Domain] Minimum [Member] Minimum Maximum [Member] Maximum Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract] Fair value assumptions Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum Risk-free interest rate, minimum (as a percent) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum Risk-free interest rate, maximum (as a percent) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Expected term Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum Expected volatility, minimum (as a percent) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum Expected volatility, maximum (as a percent) The estimated fair value of price of a single share of a number of saleable stocks of a company that is used in valuing an option on its own shares. Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Share Price Estimated fair value of the Company's common stock per share (in dollars per share) Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount [Abstract] Unrecognized compensation cost Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Unrecognized compensation cost for awards (in dollars) Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Expected period to be recognized Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent Tax at U.S. federal rate Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent State income taxes Effective Income Tax Rate Reconciliation, Other Adjustments, Percent Other permanent differences Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to transaction costs. Effective Income Tax Rate Reconciliation, Transaction Costs, Percent Transaction costs Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent Rate change Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent Research and development credit Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent Valuation allowance Effective Income Tax Rate Reconciliation, Percent Total provision Deferred Tax Assets, Gross [Abstract] Deferred tax assets Deferred Tax Assets, Operating Loss Carryforwards Net operating losses Deferred Tax Assets, Tax Credit Carryforwards, Research Research and development credit Deferred Tax Assets, Goodwill and Intangible Assets Intangible asset Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from capitalized research and development. Deferred Tax Assets, Deferred Expense, Capitalized Research and Development Costs Capitalized research and development Deferred Tax Assets, Other Other Deferred Tax Assets, Gross Gross deferred tax assets Deferred Tax Assets, Valuation Allowance Valuation allowance Deferred Tax Assets, Net of Valuation Allowance Total deferred tax assets Deferred Tax Liabilities, Net [Abstract] Deferred tax liabilities Amount of deferred tax liability attributable to taxable temporary differences from right of use asset. Deferred Tax Liabilities, Right Of Use Asset Right of use asset Deferred Tax Liabilities, Gross Total deferred tax liabilities Deferred Tax Assets, Net Net deferred tax assets and liabilities Operating Loss Carryforwards [Table] Income Tax Jurisdiction [Axis] Income Tax Jurisdiction [Domain] Domestic Tax Jurisdiction [Member] Federal State and Local Jurisdiction [Member] State Operating Loss Carryforwards [Line Items] Operating Loss Carryforwards Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount Increase in valuation allowance Operating Loss Carryforwards NOL Tax Credit Carryforward [Table] Tax Credit Carryforward [Axis] Tax Credit Carryforward, Name [Domain] Research Tax Credit Carryforward [Member] Research and development Tax Credit Carryforward [Line Items] Tax Credit Carryforward Tax Credit Carryforward, Amount Tax credit carryforward Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued Uncertain tax positions, accrued interest or penalties Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense Uncertain tax positions, interest or penalties recognized Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement [Member] Collaborative Agreement Represents information about Global Technology Transfer and License Agreement classified as a contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity. Collaborative Arrangement, Global Technology Transfer And License Agreement [Member] Global Technology Transfer And License Agreement Clinical Collaboration Agreement classified as a contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity. Collaborative Arrangement, Clinical Collaboration Agreement [Member] Clinical Collaboration Agreement Counterparty Name [Axis] Counterparty Name [Domain] Shanghai Allist Pharmaceuticals Co. Ltd. ("Allist'). Shanghai Allist Pharmaceuticals Co. Ltd. [Member] Allist Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Agreement Amount of cash outflow for cash payment made in relation to the agreement. Arrangement, Non Refundable Cash Payment Cash payment Number of shares issued in lieu of cash in execution of agreement. Stock Issued During Period, Shares, Issued in Execution of Agreement Shares issued in execution of agreement (in shares) Maximum amount payable upon achievement of certain clinical and regulatory milestone events. Arrangement, Maximum Payment, Clinical And Regulatory Milestones Maximum amount payable upon achievement of certain clinical and regulatory milestone events Maximum amount payable upon achievement of commercial milestones. Arrangement, Maximum Payment, Commercial Milestones Maximum amount payable upon achievement of commercial milestones Amount of cost reimbursement received recorded as a reduction of research and development expenses. Arrangement, Cost Reimbursement Received Cost reimbursement Amount of milestone payments made during the period. May include clinical, regulatory and commercial milestone payments. Arrangement, Payments, Milestones Milestone payments paid Alphamab Biopharmaceuticals Co., Ltd. ("Alphamab'). Alphamab Biopharmaceuticals Co., Ltd. [Member] Alphamab Maximum amount payable for combined upfront and milestone payments based on achievement of regulatory, development and sales milestones. Arrangement, Maximum Payment, Milestones Maximum amount payable upon achievement of milestones This member stands for Aarvik Therapeutics, Inc. ("Aarvik"). Also may be referred to as Aarvik Pharmaceuticals, Inc. Aarvik Pharmaceuticals, Inc [Member] Aarvik Maximum amount required to be paid on the statements of work under the agreement. Arrangement, Maximum Payment, Statement of Work Maximum payment on statements of work Amount of initiation fee payable under the agreement. Arrangement, Initiation Fee Initiation fee Payment amount made upon exercise of option to license and/or acquire certain intellectual property. Arrangement, Option to License and Acquire Intellectual Property, Payment Amount of payment to exercise option to license and/or acquire certain intellectual property Maximum amount payable per product upon achievement of certain clinical and regulatory milestone events. Arrangement, Maximum Payment Per Product, Clinical And Regulatory Milestones Maximum amount payable per product upon achievement of certain clinical and regulatory milestone events Maximum amount payable per product upon achievement of commercial milestones. Arrangement, Maximum Payment Per Product, Commercial Milestones Maximum amount payable per product upon achievement of commercial milestones Maximum amount of initiation and research fees payable under the agreement. Arrangement, Maximum Initiation and Research Fees Maximum amount of initiation and research fees to be paid Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table] Segments [Axis] Segments [Domain] Represents information pertaining to single reporting segment. Single Reportable Segment [Member] Life science Product and Service [Axis] Product and Service [Domain] Represents the information pertaining to drug Firmonertinib. Drug, Firmonertinib [Member] Firmonertinib Represents the information pertaining to Further, a product candidate containing Firmonertinib. Drug, Firmonertinib, Further [Member] Further Represents the information pertaining to Furvent, a product candidate containing Firmonertinib. Drug, Firmonertinib, Furvent [Member] Furvent Represents the information pertaining to Favour, a product candidate containing Firmonertinib. Drug, Firmonertinib, Favour [Member] Favour Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items] Segment Information Number of Reportable Segments Number of reportable segments Amount of expense for research and development for products containing specified ingredient. Excludes personnel-related and other internal costs. Research and Development Expense, Product with Specified Ingredient Research and development: Firmonertinib (excluding personnel-related and other internal costs): Amount of expense for research and development for products with specified ingredient classified as other. Research and Development Expense, Product with Specified Ingredient, Other Other Firmonertinib costs Amount of expense for research and development attributable to Discovery-stage programs. This refers to the early stages of research and development where new drug candidates or therapies are being discovered and initially tested. Research and Development Expense, Discovery Stage Programs Research and development: Discovery-stage programs Amount of expense for research and development attributable to Personnel-related and other internal costs. These are the costs associated with the people and internal resources involved in Research and Development activities. Research and Development Expense, Personnel Related and Other Internal Costs Research and development: Personnel-related and other internal costs Amount of general and administrative expense classified as personnel-related costs. These are the costs associated with the people and involved in general and administrative activities. General and Administrative Expense, Personnel Related Costs General and administrative: Personnel-related costs Other General and Administrative Expense General and administrative: Other costs Segment Reporting, Other Segment Item, Amount Other segment items Segment Reporting, Other Segment Item, Composition, Description Description of other segment item Subsequent Event [Table] Subsequent Event Type [Axis] Subsequent Event Type [Domain] Subsequent Event [Member] Subsequent Event Represents information pertaining to a License Agreement. License Agreement [Member] License Agreement Represents information pertaining to Lepu Biopharma. Lepu Biopharma [Member] Lepu Biopharma Subsequent Event [Line Items] Subsequent Events Maximum amount payable on near term milestones. Arrangement Maximum Payment Near Term Milestones Maximum amount payable upon near term milestones Maximum amount payable upon achievement of certain development, regulatory and commercial milestones. Arrangement, Maximum Development, Regulatory and Commercial Milestones Maximum amount payable upon achievement of development, regulatory and commercial milestones Rule 10b5-1 Arr Modified [Flag] Rule 10b5-1 Arr Modified [Flag] Rule 10b5-1 Arr Modified Non-Rule 10b5-1 Arr Modified [Flag] Non-Rule 10b5-1 Arr Modified [Flag] Non-Rule 10b5-1 Arr Modified